Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMNN 001

Drug Profile

IMNN 001

Alternative Names: DNA-based immunotherapy - Imunon; EGEN-001; GEN-1; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; IL-12 gene therapy - Imunon; IMNN-001; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Imunon; phIL-12-005/PPC

Latest Information Update: 20 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Expression Genetics
  • Developer Gynecologic Oncology Group; Imunon
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies
  • Mechanism of Action Gene transference; Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • No development reported Colorectal cancer
  • Discontinued Glioblastoma

Most Recent Events

  • 14 Nov 2023 IMUNON plans to submit an Investigational New Drug (IND) application for Phase I/II trial in the first quarter of 2024 in USA
  • 14 Nov 2023 Efficacy and safety data from the phase I/II OVATION 2 trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer released by IMUNON
  • 28 Sep 2023 Interim efficacy data from the phase I/II OVATION 2 trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer released by IMUNON
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top